Speaker
Shunsuke Fujino
(Japan Atomic Energy Agency)
Summary
Radioisotopes are widely utilized in Japan as diagnostic and therapeutic agents. However, Japan relies on imports for key nuclides such as Mo-99, which are produced in nuclear reactors overseas. This reliance raises concern that international circumstances could disrupt domestic supply and impede drug development. Therefore, JAEA has undertaken radioisotope production trials using the JRR-3 reactor, which resumed operation at the end of February 2021. Among these efforts, particular focuses are made on production trials for Lu-177 and Tb-161.
| Are you interested/eligible for the Young Session? | Yes, I am eligible and interested in participating |
|---|
Author
Shunsuke Fujino
(Japan Atomic Energy Agency)
